The report titled “Protein Assay Market -Forecast to 2023″ is a direct appreciation by Market Research Future of the market potential of the Protein Assay Market.
The global Protein Assay Market is expected to witness considerable growth during the forecast period, mainly due to the increasing investment by pharma and biotech companies in research and development (R&D) and funding by governments of various countries for proteomics research.
Protein Assay is an analytical technique used for measuring the concentration of protein in a solution. These assays are one of the most extensively used procedures in life science studies. Although, there is a wide range availability of protein assays, each assay is unique in its own way and has its own merits and limitations, and hence a protein assay should be selected considering their suitability for the application. For instance in Feb 2017, Promega Corporation announced the development of a benchtop capillary electrophoresis (CE) instrument in collaboration with Hitachi High-Technologies Corporation. These system are equipped to carry NGS validation, PCR sizing and microsatellite analysis, single nucleotide polymorphism, de novo sequencing and mutation detection.
Protein quantification is pivotal part of daily workflow of protein extraction in biochemistry and molecular biology labs that involves protein extraction, analysis or labeling. Favorable government policies for proteomics research, and the presence of a large number of players in the global protein assay market are the key factors driving the growth of the market during the forecast period.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5091
Most Prominent key players in the Global Protein Assays Market are GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology Inc. (U.S.), Abcam plc (U.S.), Lucigen Corporation (U.S.), PerkinElmer Inc. (U.S.), QIAGEN (Germany), Lonza Group Ltd. (Switerzland), Bio-Techne (U.S.), BioVision Inc. (U.S.), Illumina Inc. (U.S.), New England Biolabs (U.S.), Takara Bio Inc. (Japan), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switerzland), and others.
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players. For instance, in June 2015, Thermo Fisher Scientific Inc. introduced the Orbitrap Fusion Lumos Tribrid mass spectrometer and updated the device in 2017.
The protein assays is segmented on the basis of type, application, product, technology and end-users.
On the basis of type, the market is segmented into the copper-ion-based assays, test strip-based assays, dye-binding assays, and others. On the basis of application, market is segmented into diagnosis, drug discovery, protein purification and others. On the basis of product, market is segmented into reagents & kits, instruments and others. On the basis of technology market is segmented into colorimetric-based protein assays, fluorescence-based protein assays, and absorbance-based protein assays. On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.
Global protein assays consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East.
North America dominated the global protein assays market owing to the increasing research and development in biotechnology and pharmaceutical companies especially for study of genomics and proteomics play significant role in driving the global protein assays market. The European market is growing at a steady pace and is anticipated to compete with the American market. Asia Pacific is expected to be the fastest growing region in the bone graft substitute market during the forecasted period 2017 to 2023.
Browse Full Reports @ https://www.marketresearchfuture.com/reports/protein-assays-market-5091